Topline results show eDSP failed to significantly improve RmICARS scores in ataxia-telangiectasia patients compared with placebo in the NEAT trial.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment ...

The Ataxia Center at the University Hospital Bonn (UKB) and DZNE have been awarded the title “Ataxia Center of Excellence” by the US National Ataxia Foundation (NAF) for their patient care and ...

Ataxia is a condition caused by damage in cerebellum, a part of the brain, that leads to poor muscle control affecting movement. In an interview with HT Lifestyle, Dr Aniruddha More, consultant ...